tx_name,tx_abb,route,approval_dateerlotinib,erl,oral,gefitinib,gef,oral,afatinib,afa,oral,dacomitinib,dac,oral,osimertinib,osi,oral,PBDC,pbdc,IV,bevacizumab,bev,IV,nivolumab,niv,IV,pembrolizumab,pem,IV,atezolizumab,ate,IV,PBDC + bevacizumab,pbdc_bev,IV,PBDC + nivolumab,pbdc_niv,IV,PBDC + pembrolizumab,pbdc_pem,IV,PBDC + atezolizumab,pbdc_ate,IV,PBDC + bevacizumab + nivolumab,pbdc_bev_niv,IV,PBDC + bevacizumab + pembrolizumab,pbdc_bev_pem,IV,PBDC + bevacizumab + atezolizumab,pbdc_bev_ate,IV,